Oral antibiotics for community–acquired pneumonia with chest-indrawing in children aged below five years: A Systematic Review
Tóm tắt
To determine the efficacy of oral antibiotics in underfive children with pneumonia and chest indrawing. We included controlled clinical trials (randomized or quasi randomized) that compared the efficacy of oral antibiotics versus parenteral antibiotics for treatment of community- acquired pneumonia with chest-indrawing (severe pneumonia as defined by the World Health Organization’s guidelines) in children below 60 months of age. Data were extracted and managed using RevMan software. Main outcome variables were: treatment failure rate, relapse rate, death rate, need for hospitalization, and severe adverse effects. We identified four randomized controlled trials involving 4400 children who were diagnosed to have severe pneumonia but were feeding well and not hypoxic. Baseline characteristics of children in the two treatment arms (oral and parenteral antibiotics) were similar. In two studies, oral antibiotics were administered on an ambulatory basis, while in two, oral antibiotics were used in hospitalized children. Failure rate in children receiving oral antibiotics was 13% (288/2208) while that in children receiving parenteral antibiotics was 13.8% (302/2183) (OR 0.93; 95% CI 0.78, 1.11). Failure rates were not affected by the type of oral antibiotic, or presence of wheeze. Relapse rates, hospitalization or serious adverse events were similar in the two groups. Children with tachypnea with chest-indrawing without signs/symptoms of very severe pneumonia may be treated with oral antibiotics.
Tài liệu tham khảo
Liu L, Oza S, Hogan D, Perin J, Rudan I, Lawn JE, et al. Global, regional and national causes of child mortality in 2000-13, with projections to inform post-2015 priorities: An updated systematic analysis. Lancet. 2015;385:430–40.
Integrated Management of Childhood Illness: A WHO/ UNICEF initiative. Bull World Health Organization. 1997;75:(suppl. 1).
Athanassa Z, Makris G, Dimopoulos G, Falagas ME. Early switch to oral treatment in patients with moderate to severe community-acquired pneumonia: A meta-analysis. Drugs. 2008;68:2469–81.
Addo-Yobo E, Chisaka N, Hassan M, Hibberd P, Lozano JM, Jeena P, et al. Oral amoxicillin versus injectable penicillin for severe pneumonia in children aged 3 to 59 months: a randomised multicentre equivalency study. Lancet. 2004;364:1141–8.
Hazir T, Fox LM, Nisar YB, Fox MP, Ashraf YP, MacLeod WB, et al; New Outpatient Short-Course Home Oral Therapy for Severe Pneumonia Study Group. Ambulatory short-course high-dose oral amoxicillin for treatment of severe pneumonia in children: a randomised equivalency trial. Lancet. 2008;371:49–56.
Campbell H, Byass P, Forgie IM, O’Neill KP, Lloyd-Evans N, Greenwood BM. Trial of co-trimoxazole versus procaine penicillin with ampicillin in treatment of community-acquired pneumonia in young Gambian children. Lancet. 1988;2:1182–4.
RevMan 2012 Review Manager (RevMan) [Computer program]. Version 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2012.
Agweyu A, Gathara D, Oliwa J, Muinga M, Edwards T, Allen E, et al. for the Severe Pneumonia Study Group. Oral amoxicillin versus benzyl penicillin for severe pneumonia among Kenyan children: A pragmatic randomized controlled non-inferiority trial. Clin Infect Dis. 2015;60;1216–24.
Soofi S, Ahmed S, Fox MP, MacLeod WB, Thea DM, Qazi SA, et al. Effectiveness of community case management of severe pneumonia with oral amoxicillin in children aged 2-59 months in Matiari district, rural Pakistan: a clusterrandomised controlled trial. Lancet. 2012;379:729–37.
Bari A, Sadruddin S, Khan A, Khan IU, Khan A, Lehri IA, et al. Community case management of severe pneumonia with oral amoxicillin in children aged 2-59 months in Haripur district, Pakistan: a cluster randomised trial. Lancet. 2011; 378:1796–803.
Atkinson M, Lakhanpaul M, Smyth A, Vyas H, Weston V, Sithole J, et al. Comparison of oral amoxicillin and intravenous benzyl penicillin for community acquired pneumonia in children (PIVOT trial): A multicentre pragmatic randomised controlled equivalence trial. Thorax. 2007; 62:1102–6.
Bradley JS, Arguedas A, Blumer JL, Sáez-Llorens X, Melkote R, Noel GJ. Comparative study of levofloxacin in the treatment of children with community-acquired pneumonia. Pediatr Infect Dis J. 2007;26:868–78.
Chowdhury EK, El Arifeen S, Rahman M, Hoque DE, Hossain MA, Begum K, et al. Care at first-level facilities for children with severe pneumonia in Bangladesh: A cohort study. Lancet. 2008;372:822–30.
Addo-Yobo E, Anh DD, El-Sayed HF, Fox LM, Fox MP, MacLeod W, et al. Multicenter Amoxicillin Severe pneumonia Study (MASS) Group. Outpatient treatment of children with severe pneumonia with oral amoxicillin in four countries: the MASS study. Trop Med Int Health. 2011;16:995–1006.
Straus WL, Qazi SA, Kundi Z, Nomani NK, Schwartz B, Pakistan Co-trimoxazole Study Group. Antimicrobial resistance and clinical effectiveness of co-trimoxazole versus amoxycillin for pneumonia among children in Pakistan: Randomised controlled trial. Lancet. 1998;352:270–4.
Sidal M, Oðuz F, Unüvar A, Sarbat G, Neyzi O. Trial of co-trimoxazole versus procaine penicillin G and benzathine penicillin + procaine penicillin G in the treatment of childhood pneumonia. J Trop Pediatr. 1994;40:301–4.
Rojas MX, Granados C. Oral antibiotics versus parenteral antibiotics for severe pneumonia in children. Cochrane Database Syst Rev. 2006;2:CD004979.
Kabra SK, Lodha R, Pandey RM. Antibiotics for community-acquired pneumonia in children. Cochrane Database Syst Rev. 2010;3:CD004874.
Lassi ZS, Das JK, Haider SW, Salam RA, Qazi SA, Bhutta ZA. Systematic review on antibiotic therapy for pneumonia in children between 2 and 59 months of age. Arch Dis Child. 2014;99:687–93.
Global Routine Vaccination Coverage, 2011. MMWR. 2012;61:883–5.